Download PDF
Thromb Haemost 1995; 74(05): 1209-1214
DOI: 10.1055/s-0038-1649913
Review Articles
Schattauer GmbH Stuttgart

Insight into the Mechanism of Action of Heparin Cofactor II

Douglas M Tollefsen
The Division of Hematology, Department of Internal Medicine, Washington University School of Medicine, St.Louis, MO, USA
› Author Affiliations
Further Information

Publication History

Received 24 May 1995

Accepted after revision 26 July 1995

Publication Date:
10 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Bourin M-C, Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. BiochemJ 1993; 289: 313-330
    PubMedGoogle Scholar
  • 2 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma J Biol Chem 1982; 257: 2162-2169
    PubMedGoogle Scholar
  • 3 Parker KA, Tollefsen DM. The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation J Biol Chem 1985; 260: 3501-3505
    PubMedGoogle Scholar
  • 4 Ragg H. A new member of the plasma protease inhibitor gene family. Nucleic Acids Res 1986; 14: 1073-1088
    CrossrefPubMedGoogle Scholar
  • 5 Blinder MA, Marasa JC, Reynolds CH, Deaven LL, Tollefsen DM. Heparin cofactor II: cDNA sequence, chromosome localization, restriction fragment length polymorphism, and expression in Escherichia coli. Biochemistry 1988; 27: 752-759
    CrossrefPubMedGoogle Scholar
  • 6 Church FC, Meade JB, Pratt CW. Structure-function relationships in heparin cofactor II: spectral analysis of aromatic residues and absence of a role for sulfhydryl groups in thrombin inhibition. Arch Biochem Biophys 1987; 259: 331-340
    CrossrefPubMedGoogle Scholar
  • 7 Hortin G, Tollefsen DM, Strauss AW. Identification of two sites of sulfation of human heparin cofactor II. J Biol Chem 1986; 261: 15827-15830
    PubMedGoogle Scholar
  • 8 Zhang GS, Mehringer JH, Van Deerlin VM, Kozak CA, Tollefsen DM. Murine heparin cofactor II: purification, cDNA sequence, expression, and gene structure. Biochemistry 1994; 33: 3632-3642
    CrossrefPubMedGoogle Scholar
  • 9 Westrup D, Ragg H. Secondary thrombin-binding site, glycosaminoglycan binding domain and reactive center region of leuserpin-2 are strongly conserved in mammalian species. Biochim Biophys Acta 1994; 1217: 93-96
    CrossrefPubMedGoogle Scholar
  • 10 Sheffield WP, Schuyler PD, Blajchman MA. Molecular cloning and expression of rabbit heparin cofactor II: a plasma thrombin inhibitor highly conserved between species. Thromb Haemost 1994; 71: 778-782
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Herzog R, Lutz S, Blin N, Marasa JC, Blinder MA, Tollefsen DM. Complete nucleotide sequence of the gene for human heparin cofactor II and mapping to chromosomal band 22qll. Biochemistry 1991; 30: 1350-1357
    CrossrefPubMedGoogle Scholar
  • 12 Ragg H, Preibisch G. Structure and expression of the gene coding for the human serpin hLS2. J Biol Chem 1988; 263: 12129-12134
    PubMedGoogle Scholar
  • 13 Jaffc EA, Armellino D, Tollefsen DM. Biosynthesis of functionally active heparin cofactor II hy a human hepatoma-derived cell line. Biochem Bio pliys Res Comimm 1985; 132: 308-74
    PubMedGoogle Scholar
  • 14 Borriello E, Krauter KS. Multiple murine αI-protease inhibitor genes show unusual evolutionary divergence. Proc Natl Acad Sei USA 1991; 88: 9417-9421
    CrossrefPubMedGoogle Scholar
  • 15 Inglis JD, Hill RE. The murine Spi-2 proteinase inhibitor locus: a multigene family with a hypervariable reactive site domain. EMBOJ 1991; 10: 255-261
    PubMedGoogle Scholar
  • 16 Griffith MJ, Noyes GM, Tyndall JA, Church FC. Structural evidence for leucine at the reactive site of heparin cofactor II. Biochemistry 1985; 24: 6777-6782
    CrossrefPubMedGoogle Scholar
  • 17 Church EC, Noyes GM, Griffith MJ. Inhibition of chymotrypsin by heparin cofactor II. Proc Natl Acad Sci USA 1985; 82: 6431-6434
    CrossrefPubMedGoogle Scholar
  • 18 Derechin VM, Blinder MA, Tollefsen DM. Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition. J Biol Chem 1990; 265: 5623-5628
    PubMedGoogle Scholar
  • 19 Tollefsen DM, Pestka GA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716
    PubMedGoogle Scholar
  • 20 Maimone MM. Characterization of heparin and dermatan sulfate molecules that bind and activate heparin cofactor II. Ph. D. thesis Washington University; St. Louis: 1990
    Google Scholar
  • 21 Maimone MM, Tollefsen DM. Activation of heparin colactor II by heparin oligosaccharides. Biochem Biophys Res Gommun 1988; 152: 1056-1061
    PubMedGoogle Scholar
  • 22 Sié P, Petitou M, Lormeau J-C, Dupouy D, Boneu B, Choay J. Studies on the structural requirements of heparin for the catalysis of thrombin inhibition by heparin cofactor II. Biochim Biophys Acta 1988; 966: 188-195
    CrossrefPubMedGoogle Scholar
  • 23 Bray B, Lane DA, Freyssinet J-M, Pejler G, Lindahl U. Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin Biochem J 1989; 262: 225-232
    CrossrefPubMedGoogle Scholar
  • 24 Conrad HE. Structure of heparan sulfate and dermatan sulfate. Ann N Y Acad Sci 1989; 556: 18-28
    CrossrefPubMedGoogle Scholar
  • 25 Maimone MM, Tollefsen DM. Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J Biol Chem 1990; 265: 18263-18271
    PubMedGoogle Scholar
  • 26 Mascellani G, Liverani L, Prete A, Guppola PA, Bergonzini G, Bianchini P. Relative influence of different disulphate disaccharidc clusters on the HCH-mediated inhibition of thrombin by dermatan sulphates of different origins. Thromb Res 1994; 74: 605-615
    CrossrefPubMedGoogle Scholar
  • 27 Andersson TR, Larsen ML, Abildgaard U. Low heparin cofactor II associated with abnormal crossed immunoelectrophoresis pattern in two Norwegian families. Thromb Res 1987; 47: 243-248
    CrossrefPubMedGoogle Scholar
  • 28 Blinder MA, Andersson TR, Abildgaard U, Tollefsen DM. Heparin cofactor II Oslo. Mutation of Arg-189 to His decreases the affinity for dermatan sulfate J Biol Chem 1989; 264: 5128-5133
    PubMedGoogle Scholar
  • 29 Blinder MA, Tollefsen DM. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II. J Biol Chem 1990; 265: 286-291
    PubMedGoogle Scholar
  • 30 Ragg H, Ulshöfer T, Gerewitz J. On the activation of human leuserpin-2, a thrombin inhibitor, by glycosaminoglycans. J Biol Chem 1990; 265: 5211-5218
    PubMedGoogle Scholar
  • 31 Ragg H, Ulshöfer T, Gerewitz J. Glycosaminoglycan-mediated leuserpin- 2/thrombin interaction. Structure-function relationships J Biol Chem 1990; 265: 22386-22391
    PubMedGoogle Scholar
  • 32 Whinna HC, Blinder MA, Szewczyk M, Tollefsen DM, Church FC. Role of lysine 173 in heparin binding to heparin cofactor II. J Biol Chem 1991; 266: 8129-8135
    PubMedGoogle Scholar
  • 33 Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton II JW. The structure of a complex of recombinant hirudin and human a-thrombin. Science 1990; 249: 277-280
    CrossrefPubMedGoogle Scholar
  • 34 Hortin GL, Tollefsen DM, Benutto BM. Antithrombin activity of a peptide corresponding to residues 54-75 of heparin cofactor II. J Biol Chem 1989; 264: 13979-13982
    PubMedGoogle Scholar
  • 35 Van Deerlin VM D, Tollefsen DM. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of α-thrombin in the presence of glycosaminoglycans. J Biol Chem 1991; 266: 20223-20231
    PubMedGoogle Scholar
  • 36 Rogers SJ, Pratt GW, Whinna HC, Church FC. Role of thrombin exosiles in inhibition by heparin cofactor II. J Biol Chem 1992; 267: 3613-3617
    PubMedGoogle Scholar
  • 37 Phillips JE, Shirk RA, Whinna HC, Henriksen RA, Church FC. Inhibition of dysthrombins Quick I and II by heparin cofactor II and antithrombin. J Biol Chem 1993; 268: 3321-3327
    PubMedGoogle Scholar
  • 38 Sheehan JP, Wu Q, Tollefsen DM, Sadler JE. Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosile determines heparin cofactor II specificity J Biol Chem 1993; 268: 3639-3645
    CrossrefPubMedGoogle Scholar
  • 39 Griffith MJ. Heparin-catalyzed inhibitor/protease reactions: kinetic evidence for a common mechanism of action of heparin. Proc Natl Acad Sci USA 1983; 80: 5460-5464
    CrossrefPubMedGoogle Scholar
  • 40 Tollefsen DM, Peacock ME, Monalo WJ. Molecular size of dermatan sulfate oligosaccharides required to bind and activate heparin cofactor II. J Biol Ghem 1986; 261: 8854-8858
    PubMedGoogle Scholar
  • 41 Sheehan JP, Tollefsen DM, Sadler JE. Heparin cofactor II is regulated allosterically and not primarily by template effects: studies with mutant thrombins and glycosaminoglycans. J Biol Ghem 1994; 269: 32747-32751
    PubMedGoogle Scholar
  • 42 Sheehan JP, Sadler JE. Molecular mapping of the heparin-binding exosite of thrombin. Proc Natl Acad Sci USA 1994; 91: 5518-5522
    CrossrefPubMedGoogle Scholar
  • 43 Tollefsen DM, Pestka GA. Heparin cofactor II activity in patients with disseminated intravascular coagulation and hepatic failure. Blood 1985; 66: 769-774
    PubMedGoogle Scholar
  • 44 Sié P, Dupouy D, Pichon J, Boneu B. Turnover study of heparin cofactor II in healthy man. Thromb Haemost 1985; 54: 635-638
    Article in Thieme ConnectPubMedGoogle Scholar
  • 45 Pratt CW, Church FC, Pizzo SV. In vivo catabolism of heparin cofactor II and its complex with thrombin: evidence for a common receptor-mediated clearance pathway for three serine proteinase inhibitors. Arch Biochem Biophys 1988; 262: 111-117
    CrossrefPubMedGoogle Scholar
  • 46 Joslin G, Wittwer A, Adams S, Tollefsen DM, August A, Perlmutter DH. Cross-competition for binding of alpha I-antitrypsin (alpha 1 AT)-elastase complexes to the serpin-enzyme complex receptor by other serpin-enzyme complexes and by proteolytically modified alpha 1 AT. J Biol Chem 1993; 268: 1886-1893
    PubMedGoogle Scholar
  • 47 Bertina RM, van dcr Linden IK, Engesser L, Muller HP, Brommer EJ P. Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemost 1987; 57: 196-200
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Ezenagu LC, Brandt JT. Laboratory determination of heparin cofactor II. Arch Pathol Lab Med 1986; 110: 1149-1151
    PubMedGoogle Scholar
  • 49 Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P. Development of the human coagulation system in the full-term infant. Blood 1987; 70: 165-172
    PubMedGoogle Scholar
  • 50 Sandset PM, Andersson TR. Coagulation inhibitor levels in pneumonia and stroke: changes due to consumption and acute phase reaction. J Intern Med 1989; 225: 311-316
    CrossrefPubMedGoogle Scholar
  • 51 Sié P, Dupouy D, Pichon J, Boneu B. Constitutional heparin co-factor II deficiency associated with recurrent thrombosis. Lancet 1985; 2: 414-416
    PubMedGoogle Scholar
  • 52 Tran TH, Marbet GA, Duckert F. Association of hereditary heparin co-factor II deficiency with thrombosis. Lancet 1985; 2: 413-414
    PubMedGoogle Scholar
  • 53 Andersson TR, Larsen ML, Handeland GF, Abildgaard U. Heparin cofactor II activity in plasma: application of an automated assay method to the study of a normal adult population. Scand J Haematol 1986; 36: 96-102
    PubMedGoogle Scholar
  • 54 Awidi AS, Abu-Khalaf M, Herzallah U, Abu-Rajab A, Shannak MM, Abu-Obeid T, Al-Taher I, Anshasi B. Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan. Am J Hematol 1993; 44: 95-100
    CrossrefPubMedGoogle Scholar
  • 55 Andrew M, Mitchell L, Berry L, Paes B, Delorme M, Ofosu F, Burrows R, Khambalia B. An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus. J Clin Invest 1992; 89: 321-326
    CrossrefPubMedGoogle Scholar
  • 56 Brennan MJ, Oldberg A, Pierschbacher MD, Ruoslahti E. Chondroitin/dermatan sulfate proteoglycan in human fetal membranes: demonstration of an antigenically similar proteoglycan in fibroblasts. J Biol Chem 1984; 259: 13742-13750
    PubMedGoogle Scholar
  • 57 Massouh M, Jatoi A, Gordon EM, Ratnoff OD. Heparin cofactor II activity in plasma during pregnancy and oral contraceptive use. J Lab Clin Med 1989; 114: 697-699
    PubMedGoogle Scholar
  • 58 Liu L, Dewar L, Song Y, Kulczycky M, Blajchman MA, Fenton II JW, Andrew M, Delorme M, Ginsberg J, Preissner KT, Ofosu FA. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Thromb Haemost 1995; 73: 405-412
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 Sandset PM, Hellgren M, Uvebrandt M, Bergström H. Extrinsic coagulation pathway inhibitor and heparin cofactor II during normal and hypertensive pregnancy. Thromb Res 1989; 55: 665-670
    CrossrefPubMedGoogle Scholar
  • 60 McGuire EA, Tollefsen DM. Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells. J Biol Chem 1987; 262: 169-175
    PubMedGoogle Scholar
  • 61 Hiramoto SA, Cunningham DD. Effects of fibroblasts and endothelial cells on inactivation of target proteases by protease nexin-1, heparin cofactor II, and Cl-inhibitor. J Cell Biochem 1988; 36: 199-207
    CrossrefPubMedGoogle Scholar
  • 62 Whinna HC, Choi HU, Rosenberg LC, Church FC. Interaction of heparin cofactor II with biglycan and decorin. J Biol Chem 1993; 268: 3920-3924
    PubMedGoogle Scholar
  • 63 Coughlin SR, Vu T-KH, Hung DT, Wheaton VI. Characterization of a functional thrombin receptor. Issues and opportunities J Clin Invest 1992; 89: 351-355
    CrossrefPubMedGoogle Scholar
  • 64 Church FC, Pratt CW, Hoffman M. Leukocyte chemoattractant peptides from the serpin heparin cofactor II. J Biol Chem 1991; 266: 704-709
    PubMedGoogle Scholar